2016
Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcoma.
Abu-Khalaf MM, Raza MA, Hatzis C, Wang H, Lin K, Higgins S, Ratner E, Silasi DA, Azodi M, Rutherford TJ, Santin AD, Schwartz PE. Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcoma. European Journal Of Gynaecological Oncology 2016, 37: 199-203. PMID: 27172745.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnemiaAntineoplastic Combined Chemotherapy ProtocolsBrachytherapyCarcinosarcomaChemoradiotherapyCisplatinDisease-Free SurvivalFemaleHumansIfosfamideMesnaMiddle AgedNeoplasm StagingNeutropeniaProtective AgentsRetrospective StudiesTreatment OutcomeUterine NeoplasmsConceptsVaginal cuff brachytherapyProgression-free survivalFirst-line treatmentOverall survivalUterine carcinosarcomaStage ILine treatmentStage IIIDay 1Anemia grade 1Most common toxicitiesNeutropenia grade 3Cycles of cisplatinMedian overall survivalStage IV diseaseCommon toxicitiesMedian followTreatment discontinuationFree survivalPatient withdrawalCombination cisplatinDose modificationMedian ageRetrospective studyGrade 3
2007
Carcinosarcoma of the ovary
SILASI D, ILLUZZI JL, KELLY MG, RUTHERFORD TJ, MOR G, AZODI M, SCHWARTZ PE. Carcinosarcoma of the ovary. International Journal Of Gynecological Cancer 2007, 18: 22-29. PMID: 17451459, DOI: 10.1111/j.1525-1438.2007.00948.x.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinosarcomaChemotherapy, AdjuvantCisplatinCombined Modality TherapyDisease-Free SurvivalFemaleHumansIfosfamideMiddle AgedOvarian NeoplasmsPaclitaxelRegistriesRetrospective StudiesSurvival RateTreatment OutcomeConceptsProgression-free intervalMedian progression-free intervalAdvanced stage diseaseMedian survivalOptimal cytoreductionOvarian carcinosarcomaStage diseaseTaxol groupEffective cytotoxic regimenFirst-line cisplatinFirst-line chemotherapyCombination of carboplatinEpithelial ovarian cancerCytotoxic regimenIfosfamide groupAdjuvant cisplatinEntire cohortMedical recordsOvarian cancerCytoreductionPatientsSurvival rateCarcinosarcomaCarboplatinCisplatin